[ Inside the business ]

INCY stock analysis

INCY · Incyte Corp

Services-commercial physical and biological research. Growing 14%. Keeps 10¢ of every dollar.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 1.6× sales in 5 yrs. Evidence: sales +14% · 10¢ profit/$1.

01 What's priced in?1.6× sales in 5 yrs
Sales now$6.0B
Needed in 5 yrs$9.4B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Customer C: 21% of sales
Customer C 21%Customer D 18%Customer A 13%Customer E 11%Everyone else
Prepaid $9MSales +14%, slowing
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 10¢ per $1, falling
'21'22'23'24'2510¢
Before running costs: 94% → 93%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −5.7%/yrDebt $0
07 What could break it?3 to watch
  • Growth peaked
  • Insiders sold $49M outside pre-set plans
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth peaked.

Sales growth +21%, +38%, then +14% vs. a year ago.

What could go wrong

Steadier than most.

It has moved 0.7× the market. In the 2008 crisis it fell 73% while the market fell 51%. Debt is covered by cash.

Speculative check

Not classified.

Not Self-funding because of: loss in the latest quarter.

What they sell

53% JAKAFI.

JAKAFI 53% · OPZELURA 16% · JAKAVI Royalty Revenues 9% · NIKTIMVO 4% · other (latest quarter)

Where each dollar goes

10¢ profit.

7¢ to make what it sells, 82¢ on research and overhead, 10¢ left over. Revenue $6.0B in the last 12 months.

Its market

1.6× the economy.

The government expects its industry, scientific research and development services, to grow 3.1% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Growth.

It earns cash, invests heavily, and still raises money to grow.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 185¢ of each $1 of profit.

Competitive advantage

4 of 10 years.

Returns beat its 8.8% cost of capital in 4 of the last 10 years. Gross margin went from 95% to 93%.

Future bets

57% on research.

$3.4B a year on R&D.

All figures from Incyte Corp's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.